Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
BACKGROUNDAn increase in intrahepatic triglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear.METHODSHepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both liver and whole-body insulin sensitivity were determined in individuals who were lean (n = 14), obese with normal IHTG content (n = 26), or obese with NAFLD (n = 27). Hepatic DNL was assessed using the deuterated water method corrected for the potential confounding contribution of adipose tissue DNL. Liver and whole-body insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose tracer infusion. Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%.RESULTSThe contribution of hepatic DNL to IHTG-palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively. Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations. Weight loss decreased IHTG content, in conjunction with a decrease in hepatic DNL and 24-hour plasma glucose and insulin concentrations.CONCLUSIONSThese data suggest hepatic DNL is an important regulator of IHTG content and that increases in circulating glucose and insulin stimulate hepatic DNL in individuals with NAFLD. Weight loss decreased IHTG content, at least in part, by decreasing hepatic DNL.TRIAL REGISTRATIONClinicalTrials.gov NCT02706262.FUNDINGThis study was supported by NIH grants DK56341 (Nutrition Obesity Research Center), DK20579 (Diabetes Research Center), DK52574 (Digestive Disease Research Center), and RR024992 (Clinical and Translational Science Award), and by grants from the Academy of Nutrition and Dietetics Foundation, the College of Natural Resources of UCB, and the Pershing Square Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, DNL has been associated with hepatic and whole-body IR (glucose metabolism),24,25 suggesting that IR may accelerate hepatic DNL.25”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [25]
In the citing paper
“In a well-designed study by Smith et al. [50], the contribution of hepatic DNL to intrahepatic TG palmitate was 11%, 19%, and 38% in the lean, obese, and obese-MASLD groups, respectively.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
In the citing paper
“Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“First, the long (3-5 week) duration of D2O tracer administration in our study accounted for labelling of the liver TG pools that turn over slowly (12) and provided an integrated assessment of DNL during daily fasting and fed conditions over several weeks.”
BackgroundMethodResultInfluentialA new predictive equation for resting energy expenditure in healthy individuals
Mifflin, M., St Jeor, S., Hill, L., Scott, B., Daugherty, S., & Koh, Y. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.2.241 · Cited by 2,544 · cited 2×
“The initial daily energy content of the diet provided 75% of estimated energy requirements (54); subsequent meals and energy”
BackgroundMethodObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Self-citationNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 1×
“Although the mechanism(s) responsible for the increase in hepatic DNL in people with NAFLD is not known, it is possible that increases in circulating insulin and glucose associated with hepatic and whole-body insulin resistance are involved in stimulating hepatic DNL because insulin and glucose activate SREBP-1c and C…”
Background
Research works printed but not linked: 2
- 10.1172/JCI22422 · DOI · Paper page
- 10.1016/S1097-2765(05)00010-9 · doi:10.1016/s1097-2765(05)00010-9 · Paper page
Cited by
Items 601–700 of 770
You, Y., Guo, Y., Guan, X., Zhong, G., Yin, Y., Yin, Z., Wen, Y., Li, W., Zhao, H., Chen, S., et al. (2026) · Environmental Pollution · doi:10.1016/j.envpol.2026.127985 · Cited by 1
Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption
Bril, F., Forbes, S. C., Kalavalapalli, S., & Cusi, K. J. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag125 · Cited by 2
PLAKIDA, A. L., Юшковська, О., & Sierpińska, L. E. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i3.113284 · Cited by 1
Current management of MASLD in type 2 diabetes
Fernández‐Garibay, V. M., Sarabia-Chao, V., & Chávez-Tapia, N. C. (2026) · HORMONES · doi:10.1007/s42000-026-00763-6 · Cited by 1
Transcutaneous allicin oleogel restores energy homeostasis for obesity treatment
Xu, Q.-G., Gu, Z.-Y., Chen, W.-J., Liu, H., Li, Z.-Y., Cai, W.-L., Huang, J., Muhitdinov, B. I., Liu, E.-G., Aisa, H. A., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01768-y · Cited by 2
“This leads to an increase in the synthesis of triglycerides in the liver while reducing their output, thereby exacerbating hepatic steatosis (fatty degeneration of liver cells) [35].”
Xuan, Y., Wu, D., & Yao, Q. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1818931 · Cited by 1
Exercise as a Metabolic Therapy for MASLD: Beyond Weight Loss Toward Sustainable Exercise Strategies
Roh, H., & Bae, J. Y. (2026) · Medicina · doi:10.3390/medicina62040784 · Cited by 1
“Accordingly, MASLD should be understood as a disorder of dysregulated lipid and glucose metabolism, underscoring the importance of mechanistic approaches targeting systemic metabolism [9].”
Zhang, T., Man, Z. Y., Zhang, S.-M., Mu, J. J., & Liao, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1805355 · Cited by 1
ChREBP-mediated regulation of lipid metabolism in liver and brown adipose tissue of long-lived mice
Hager, M., Adam, C., Mercier, L., Voorhees, A., Lee, M., Ball, L., Yang, J., Bartke, A., Miller, R. A., & Li, X. (2026) · GeroScience · doi:10.1007/s11357-026-02263-2 · Cited by 1
Klisic, A. N., Tomašević, R., Đjurašković, S., Mercantepe, F., & Ninić, A. (2026) · Archives of Medical Science · doi:10.5114/aoms/219846 · Cited by 7
“Consequently, there is an increased influx of FFAs into the liver, driven both by reduced inhibition of lipolysis and by an increase in de novo synthesis of FFAs [49].”
Won, J.-H., Baek, K., Xiang, Y.-Y., & Kim, J. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00568.2025 · Cited by 1
Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease
Davidson, N. O. (2026) · Circulation Research · doi:10.1161/circresaha.126.327269 · Cited by 2
Yu, Q., Liu, M., He, L., & Hua, F. (2026) · Medicine · doi:10.1097/md.0000000000049183 · Cited by 1
Precision nutrition in MASLD should incorporate metabolic and inflammatory phenotyping
Ntikoudi, A. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1820240 · Cited by 1
“Korenblat et al. (6) and Smith et al. (7) demonstrated that hepatic de novo lipogenesis is markedly increased in insulin-resistant individuals and strongly correlated with intrahepatic triglyceride content.”
Yue, Z., Tang, Y., Wang, Y., Wang, Z., Xi, R., & Qian, L. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1875732 · Cited by 1
Rating Agencies: Creating, Amplifying or Drawn by Events in the Sovereign Debt Crisis?
Url, T. (2012) · Austrian Economic Quarterly · Cited by 1
Welles, J. E., Lacko, H. A., Kawasawa, Y. I., Dennis, M. D., Jefferson, L. S., & Kimball, S. R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032293 · Cited by 1
“Nonalcoholic fatty liver disease (NAFLD) refers to a spectrum of conditions ranging from nonalcoholic liver (NAFL) to nonalcoholic steatohepatitis (NASH) and is the most common cause of chronic liver failure worldwide and is the second leading indicator for liver transplant (1, 2).”
BackgroundInfluentialDiabetes, Aging, and Insulin’s Reponic Features: Review
Moen, J. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666221031140713 · Cited by 1
Adiwinoto, R. D., Pranoto, A. S., Sugihartono, T., Soelistijo, S. A., & Adiwinoto, R. P. (2024) · International Journal of Public Health Science (IJPHS) · doi:10.11591/ijphs.v13i3.24035 · Cited by 1
“Insulin resistance also induces de novo lipogenesis, thereby further increases liver fat content [27].”
BackgroundSaroglitazar - A novel treatment for non-alcoholic steatohepatitis
Noorani, S., Ankam, M., Ganesh, C. H. S. V., Banu, R., Vani, P., Polarapu, N., Jangra, S., Shaima, K. A., & Bhyan, B. (2024) · AIP conference proceedings · doi:10.1063/5.0228900 · Cited by 1
Varicose vein disease in the context of insulin resistance
Korolenya, V. A., Филипенко, М. Л., & Smetanina, M. A. (2024) · Vessel Plus · doi:10.20517/2574-1209.2024.26 · Cited by 2
Yuan, H., Zhou, J., Zhang, T., Wu, X., Li, C., Yang, H.-J., Jeong, D., & Park, S. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.105720 · Cited by 2
Associations of erythrocyte membrane fatty acids with blood pressure in children
Huang, L., Li, S., Zhou, Q., Ruan, X., Wu, Y., Wei, Q., Xie, H., & Zhang, Z. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2024.12.035 · Cited by 1
Bhuvaneswari, D., Riitvek, B., & Lakshmi, B. S. (2025) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-05142-8 · Cited by 1
“Insulin resistance in the major tissues such as skeletal muscle, adipose tissue and liver leads to an imbalance in glucose and lipid metabolism [24].”
Wen, Y., Li, J., Mukama, O., Huang, R., Deng, S., & Li, Z. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.03.007 · Cited by 1
Naidoo, K., & Khathi, A. (2025) · Molecules · doi:10.3390/molecules30081834 · Cited by 3
“Hyperinsulinemia, elevated glucose, and free fatty acid flux into the liver upregulates hepatic de novo lipogenesis through steroid regulatory elementary binding protein-1c [6].”
Surprising findings in a ‘well-understood’ nutrient-assimilation pathway
Hellerstein, M. K. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0242-5 · Cited by 1
Self-citationThe solution to obesity and type 2 diabetes: reversing insulin resistance
Alizadeh, H. (2021) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2021-0053 · Cited by 1
NAFLD et NASH au cours du diabète : données épidémiologiques, cliniques et pronostiques
Béland‐Bonenfant, S., Petit, J., & Vergès, B. L. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.03.011 · Cited by 3
Carbohydrate, Protein, and Fat Metabolism in Obesity
Galgani, J. E., Cortés, V., & Carrasco, F. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_21 · Cited by 1
Chop / Ddit3 depletion in β-cells alleviates ER stress and corrects hepatic steatosisPreprint
Yong, J., Parekh, V. S., Nayak, J., Chen, Z., Lebeaupin, C., Zhang, J., Prakash, T. P., Murray, S., Guo, S., Ayala, J. E., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.02.893271 · Cited by 1
“Echoing the recently reported human study (7), it will be 79 of interest to investigate if the improvement of fatty liver we observed here 80 reflects reduced de novo hepatic lipogenesis.”
BackgroundInfluentialTrouwborst, I. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230202it · Cited by 1
Ho, K. C.-Y., & Mak, L. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103119 · Cited by 1
Azhar, M., Worsley, J., Dennis, K. M. J. H., Rolfe, E. D. L., Barrett, A., Mandour, M. O., Demir, E., Carr, K., Ferraro, M., Jesus, R. D., et al. (2025) · medRxiv · doi:10.1101/2025.11.01.25339296 · Cited by 1
Nonalcoholic fatty liver disease in relation to cardiovascular disease: Is all fat equal?
Simons, N. (2020) · Research Publications (Maastricht University) · doi:10.26481/dis.20210226ns
Anti-Diabetic Medications: A promising therapeutic approaches for the Management of NAFLD
Ibrahim, A. Z., Hazem, R. M., Ali, D. A., & Moustafa, Y. M. (2021) · Records of Pharmaceutical and Biomedical Sciences/Records of Pharmaceutical & Biomedical Sciences · doi:10.21608/rpbs.2021.79353.1103
Guo, W., Qin, P., Li, X., Lu, J., Zhu, W., Wu, J., Xu, N., & Zhang, Q. (2020) · Research Square · doi:10.21203/rs.3.rs-109731/v1
Association of type 2 diabetes mellitus and other glycemic traits with the risk of NAFLDPreprint
Guo, Z., Kong, D., Du, H., Yun, Z., Zhang, J., Li, X., & Ye, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-2377438/v1
Impact of physical exercise on metabolic dysfunction-associated fatty liver disease (MAFLD)
Sales, S. T., Gasparini, P. V. F., Madureira, A. R., Cordeiro, J. P., Leopoldo, A. S., & Lima‐Leopoldo, A. P. (2023) · Brazilian Journal of Development · doi:10.34117/bjdv9n1-053 · Cited by 1
Mucinski, J. M. (2022) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/93980
Morphometric analysis of fatty liver with the treatment of ginseng root extract
Rehan, R., Imtiaz, F., Jabeen, S., Haq, A. A., Mubeen, S., & Memon, F. M. (2023) · INTERNATIONAL JOURNAL OF ENDORSING HEALTH SCIENCE RESEARCH (IJEHSR) · doi:10.29052/ijehsr.v11.i1.2023.42-53
Biochemical Profiles of Different Approaches Applied to Induction of Diabetes in Rats
Ali, M. A., & Mustafa, N. G. (2023) · Egyptian Journal of Veterinary Science · doi:10.21608/ejvs.2023.194510.1445 · Cited by 3
“The strong association between diabetes and dyslipidemia is confirmed by many authors [30-34].”
BackgroundLiver Fat – Gone, but Not Forgotten?
Titchenell, P. M., & Baur, J. A. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.04.008
“Notably, an increase in de novo lipogenesis is a hallmark of NAFLD and is established to be a major driving force behind the increased hepatic lipids in NAFLD.4,5 Finally, in the absence of stellate cells and an active immune system, it is not clear that cultured hepatocytes will be able to mimic the complete transiti…”
BackgroundHeeba, G. H., Abolnaga, M., & Othman, E. M. (2023) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2023.301257
Giannoukakis, N., & McCommis, K. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1253604
Carbohydrate, Protein, and Fat Metabolism in Obesity
Galgani, J. E., Cortés, V., & Carrasco, F. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_21-2
Combatting the Fructose Epidemic: Fruitful or Fruitless?
Buziau, A. M. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231113ab
Mechanism for FXR to regulate bile acid and glycolipid metabolism to improve NAFLD
Huang, Z. G., & Zhou, R. (2023) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v31.i19.797
Soldatenkova, N. A., Владимировна, Г. И., & Мазурчик, Н. В. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-3-40-45
Dong, B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91338-6.00027-6
Bayesian Single-Arm Meta-Analysis of Nonalcoholic Fatty Liver Disease in China in Recent 10 Years
文, 永. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13122772
Zhang, J., Chen, H., Wang, S., Zhang, Z., Chen, X., Wang, S., Wang, W., Zhou, H., Ding, Y., & Kong, D. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4676980
Scientific Exercises and Right Diet-The Consummate Combination for an Incontrovertible Metabolism
Balachandar, J. C., Ahamed, S. I., & Jayachandran, M. (2023) · Endocrine System and Diabetes · doi:10.58489/2836-502x/008
Mdluli, W., Aswani, H. S., & Khathi, A. (2023) · JMIR Research Protocols · doi:10.2196/49486
Guizar-Heredia, R., Guevara‐Cruz, M., Aguilar‐López, M., González-Salazar, L. E., Vera, I., Arteaga-Sánchez, L., Pichardo‐Ontiveros, E., Serralde-Zúñiga, A. E., Díaz‐Villaseñor, A., Ávila-Nava, A., et al. (2024) · Clinical Nutrition Open Science · doi:10.1016/j.nutos.2024.03.009
“…may also be related to proin fl ammatory cytokines released by adipose tissue, which play a central role in the pathogenesis of T2D and non-alcoholic fatty liver disease (NAFLD) and lipid metabolism by promoting de novo lipogenesis, and hepatic de novo lipogenesis contributing to steatosis [32,33].”
Physalis peruviana intake against noncommunicable chronic diseases: a biomedical approach
Luis, P., Nocetti, D., & Alejandra, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15433-1.00030-3
Kano, H. T. (2023) · Novel Techniques in Nutrition & Food Science · doi:10.31031/ntnf.2023.07.000658
Nonalcoholic fatty liver disease: What comes before and what are the consequences?
Bril, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00017-8
Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Makri, E. S. (2024) · Annals of Gastroenterology · doi:10.20524/aog.2024.0884 · Cited by 1
“Insulin resistance (IR) represents another major contributor to the pathogenesis of NAFLD, since it leads to oversupply of free fatty acids to the liver, as a result of the increased lipolysis of adipose tissue triglycerides and hepatic de novo lipogenesis [28,29].”
BackgroundDhillon, J., Pandey, S., Newman, J. W. I., Fiehn, O., & Ortiz, R. M. (2024) · medRxiv · doi:10.1101/2024.05.19.24307571
“The improvement in insulin sensitivity observed in the almond group may facilitate more efficient lipid metabolism, potentially reducing hepatic de novo lipogenesis [26] and the risk of hepatic steatosis.”
BackgroundLi, Z., Liu, R., Gao, X., Hou, D., Leng, M., Zhang, Y., Du, M., Zhang, S., & Li, C. (2024) · Research Square · doi:10.21203/rs.3.rs-4505877/v1
Andrade, L. J. D. O., de Oliveira, G. C. M., & de Oliveira, L. M. (2024) · Research Square · doi:10.21203/rs.3.rs-4739938/v1
Topal, G. G., Sevim, S., Gümüş, D., Balaban, H. Y., Karçaaltıncaba, M., & Kızıl, M. (2024) · PeerJ · doi:10.7717/peerj.17810
“This elevated lipogenesis contributes to the accumulation of triglycerides in hepatocytes, a characteristic feature of NAFLD ( Smith et al., 2020 ; Softic et al., 2017 ).”
BackgroundMathematical Modelling of MASLD ‐ Towards Digital Twins in Liver Disease
Simonsson, C. (2024) · Linköping studies in science and technology. Dissertations · doi:10.3384/9789180757348
Zhao, Q., Li, Y., Zhang, M., & Ban, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-71608-8
Cook, J. R., Bedeir, N., Sone, Z. D., Wattacheril, J. J., Ginsberg, H. N., & Laferrère, B. (2024) · Diabetes · doi:10.2337/db24-0402
Chronische Erkrankungen – eine Versorgungsherausforderung
Eble, S. (2024) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-66798-9_10-1
Li, F., Chen, J., Xu, Y., Wang, M., Sun, S., & Zhou, S. (2024) · Natural Product Communications · doi:10.1177/1934578x241293660
Liver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 3
Zhou, J., Shi, Y., Bao, Z., Luo, M., Li, J., Rashed, M. M. A., Xu, S., Yang, J., Duan, H., Hu, H., et al. (2025) · Food Science and Human Wellness · doi:10.26599/fshw.2025.9250472
Advances in the Pathogenesis of Metabolism-Related Fatty Liver Disease
苏, 红. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1541234
Wu, F., Zhang, J., Sun, W., Li, J., Zhang, W.-Q., & Bai, M. (2025) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v33.i4.308
Wu, F. H., Zhang, J., Sun, W., Li, J., Zhang, W., & Bai, M. (2025) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v33.i4.301
Khan, M. M., Khan, Z. A., Khan, M. A., & Pandey, G. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i7.106194
Sun, L., Liu, Y., Sun, Y., Huang, X., & Wang, G. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5361001
Suryaningtyas, I. T., Jung, W., Lee, S., & Je, J. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501190 · Cited by 1
“FAS is a key enzyme in de novo lipogenesis, and its inhibition is linked to reduced fat accumulation [42, 43].”
Vitamin E as a Therapeutic Agent for NAFLD: A Systematic Review of Randomized Controlled Trials
Liu, C., Bai, Z., & Cheng, J. (2025) · American Journal of Internal Medicine · doi:10.11648/j.ajim.20251304.12
Sato, K., Irie, Y., Asai, H., Yoshioka, S., Murakawa, K., Sho, H., Inui, R., Kosugi, M., Hazama, Y., & Yasuda, T. (2025) · Internal Medicine · doi:10.2169/internalmedicine.6239-25 · Cited by 1
“Chronic hyperglycemia and hyperinsulinemia, secondary to insulin resistance, promote fat accumulation in the liver by enhancing de novo lipogenesis and inhibiting fat oxidation (21).”
Role of the xenobiotic-activated pregnane X receptor in type 1 and type 2 diabetes in male mice
Nnamani, D. O., Choi, S., Ofosu‐Boateng, M., Gebreyesus, L. H., Twum, E., Polunas, M., Goedken, M. J., Yadak, N., Dagogo-Jack, S. E., Ahima, R. S., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117482
Gwag, T., Newcomb, A., Otuagomah, J., Murray, S., Guo, S., Tong, S., Kern, P. A., & Wang, S. (2025) · Aging · doi:10.18632/aging.206343
Revealing the biochemical regulations of L-PGDS in hepatic insulin-resistance using HepG2 cells
Khairnar, R., Islam, M. A., Singh, K., Shetty, D. K., Yadav, A., Dukhande, V. V., & Kumar, S. (2025) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2025.107052
A nomogram for assessing the risk of MAFLD based on the albumin-to-gamma-glutamyl transferase ratio
Meng, S., Li, L. J., Liu, Y., Yin, S., Zhao, Y., Zhang, Y., Zhang, X., & Yu, F. (2025) · European journal of medical research · doi:10.1186/s40001-025-03594-0
“Because insulin levels are not routinely measured in the clinical context, the Homeostasis Model Assessment of Insulin Resistance (HOMA–IR) is limited in its ability to assess IR [26].”
Gijbels, A., Erdõs, B., Trouwborst, I., Jardon, K. M. C., Adriaens, M. E., Goossens, G. H., Blaak, E. E., Feskens, E. J. M., & Afman, L. A. (2024) · Figshare · doi:10.6084/m9.figshare.25424822
Gijbels, A., Erdõs, B., Trouwborst, I., Jardon, K. M. C., Adriaens, M. E., Goossens, G. H., Blaak, E. E., Feskens, E. J. M., & Afman, L. A. (2024) · Figshare · doi:10.6084/m9.figshare.25424775
Li, Z., Liu, R., Gao, X., Hou, D., Leng, M., Zhang, Y., Du, M., Zhang, S., & Chunjun, L. I. (2024) · Figshare · doi:10.6084/m9.figshare.26746973
Batista, E. S., da Silva Rios, T., Muñoz, V. R., Jesus, J. S., Vasconcelos, M. M., da Cunha, D. T., Marques-Rocha, J. L., Nakandakari, S. C. B. R., Lara, R., da Silva, A. S. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17284452
Kerlikowsky, F., & Hahn, A. (2025) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2025.200346
Hariharan, V., & Vijayasamundeeswari, C. K. (2025) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/jcmk/17414
Tavaglione, F., Ajmera, V. H., Díaz, L. A., Li, K., Madamba, E. V., Bettencourt, R., Richards, L., Hellerstein, M. K., & Loomba, R. S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101733
Self-citationChristoper, A., Herman, H., Abdulah, R., Zulhendri, F., Popova, M., Trusheva, B., Bankova, V. S., & Lesmana, R. (2026) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-05236-8
“Insulin resistance and high glucose levels will trigger de novo lipogenesis (DNL) in the liver, which will cause high FFAs production in the liver [39–41].”
Yakut, S., Ulaş, N., & İmik, A. (2026) · Veteriner Hekimler Derneği Dergisi · doi:10.33188/vetheder.1790255
Koo, Y., Lee, J. Y., Kim, M. J., & Lee, Y. (2026) · Journal of Medicinal Food · doi:10.1177/1096620x251412893
“33 Lipolysis generates fatty acids through the stepwise hydrolysis of triacylglycerols; these fatty acids undergo b -oxidation to produce acetyl-CoA for the citric acid cycle.”
Pathogenesis of type 2 diabetes
Honka, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00376-9
Yu, H., Zhang, J., Sun, P.-Q., Li, Q.-H., Lin, H., Wang, J.-Y., Qian, X.-J., Yang, X., Hu, C., 田平, et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1737860
Xu, H., Zhao, X., Bai, H., & Li, S. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1807050 · Cited by 1
“Particularly under conditions of high-sugar and high-fat diet (HFD) or insulin resistance, persistent enhancement of de novo lipogenesis is regarded as one of the central driving forces underlying the initiation and progression of non-alcoholic fatty liver disease (39).”
Liu, N., Qian, X., Yang, L., Chang, X., Long, C., Chen, D., Zheng, Z., Zhang, K., & Xu, C. (2026) · European journal of medical research · doi:10.1186/s40001-026-04180-8
Fuel toxicity-associated spectrum (FTAS): a unifying nomenclature for metabolic disorders
Sureshkumar, P. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00282-8
“Critically, insulin resistance itself can further drive hepatic de novo lipogenesis, creating a vicious cycle of ectopic fat accumulation and metabolic dysfunction [44].”
Carter, S., Bradshaw, L., Spellanzon, B., Johnson, E. M., Koumanov, F., Dennis, K. M. J. H., Start, C. A. T., Moreno‐Cabañas, A., Vincent, E. E., MAHER, J. L., et al. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00074.2026 · Cited by 1
Metadata
- Authors
- Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., Sirlin, C. B., Talukdar, S., Hellerstein, M. K., & Klein, S.
- Affiliations
- Washington University in St. Louis (US)
- University of California, Berkeley (US)
- University of California San Diego (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Klein, Samuel
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-04
- Volume
- 130
- Issue
- 3
- Pages
- 1453-1460
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7269561
- OpenAlex
- W2993862932
- Cited by
- 771
- References
- 65
- Citations by year
- 2026: 121 · 2025: 136 · 2024: 153 · 2023: 123 · 2022: 104 · 2021: 92 · 2020: 40
- FWCI
- 44.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (DK56341,DK20579,DK52574,RR024992)
- College of Natural Resources, University of California at Berkeley (N/A)
- Pershing Square Foundation (N/A)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, hepatic de novo lipogenesis, insulin resistance, intrahepatic triglyceride, hepatic insulin sensitivity, weight loss, obesity, hepatic steatosis, plasma glucose, hyperinsulinemic-euglycemic clamp
- MeSH terms
- Adult, Blood Glucose, Female, Humans, Insulin, Insulin Resistance, Liver, Male, Triglycerides, Palmitic Acid, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.